Lipid lowering efficacy between morning and evening simvastatin treatment: A randomized double-blind study

Journal of the Medical Association of Thailand

Volumn 93, Issue SUPPL 7, 2010, Pages

  Tharavani, Thipaporn ^a   Wongtanakar, Sirichai ^a   Lerdvuthisopo, Nusiri ^a   Teeraaunku, Sugree ^b   Youngsriphitha, Pilasinee ^b   Sritipsukh, Paskorn ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

^b THAMMASAT UNIVERSITY HOSPITAL   (Thailand)

Author keywords

Efficacy; Evening; Lipid; Morning; Simvastatin

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952504256     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Pappu AS, Illingworth DR. The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002; 165: 137-44.
2. Plosker GL, McTavish D. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1995; 50: 334-63.
3. Lund TM, Torsvik H, Falch D, Christophersen B, Skardal R, Gullestad L. Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease. Am J Cardiol 2002; 90: 784-6.
4. Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A doubleblind comparative study. Arterioscler Thromb 1991; 11: 816-26.
5. Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ 2003; 327: 788.
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
7. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-5.
8. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-3.
9. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
10. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2: 208-17.
11. Kostakou P, Kolovou G, Anagnostopoulou K, Theodoridis T, Galea V, Mihas C, et al. Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand's factor and C-reactive protein in patients with hypercholesterolaemia. Arch Cardiovasc Dis 2010; 103: 26-32.